Standardization of metaiodobenzylguanidine heartto mediastinum ratio using a calibration phantom: Effects of correction on normal databases and a multicentre study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 1, 2012, Pages 113-119

  Nakajima, Kenichi ^a   Okuda, Koichi ^a   Matsuo, Shinro ^a   Yoshita, Mitsuhiro ^a   Taki, Junichi ^a   Yamada, Masahito ^a   Kinuya, Seigo ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

123I metaiodobenzylguanidine; Calibration phantom; Heart to mediastinum ratio; Lewy body disease; Standardization

Indexed keywords

(3 IODOBENZYL)GUANIDINE; IODINE 123; DIAGNOSTIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CALIBRATION; CAMERA; CHI SQUARE TEST; COLLIMATOR; CONTROLLED STUDY; DATA BASE; DIGITAL IMAGING; FEMALE; HOSPITAL; HUMAN; JAPAN; LEWY BODY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MULTICENTER STUDY; PHANTOM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARDIZATION; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; FACTUAL DATABASE; HEALTH CARE ORGANIZATION; HEART MUSCLE; IMAGE QUALITY; INSTRUMENTATION; METABOLISM; RETROSPECTIVE STUDY; SCINTISCANNING; STANDARD;

3-IODOBENZYLGUANIDINE; AGED; ALZHEIMER DISEASE; CALIBRATION; DATABASES, FACTUAL; DIAGNOSIS, DIFFERENTIAL; HUMANS; LEWY BODY DISEASE; MEDIASTINUM; MYOCARDIUM; PHANTOMS, IMAGING; REFERENCE STANDARDS; RETROSPECTIVE STUDIES; SOCIETIES, SCIENTIFIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84858727909     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1963-1     Document Type: Article

References (25)

1. Merlet P, Valette H, Dubois-Randé JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.
2. Matsunari I, Schricke U, Bengel FM, Haase HU, Barthel P, Schmidt G, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000;101:2579-85. (Pubitemid 30350635)
3. Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol 2009;16:113-21.
4. Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M, Matsumoto Y, Nakajima K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006;66:1850-4. (Pubitemid 44049815)
5. Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S. Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging 2008;52:378-87.
6. Estorch M, Camacho V, Paredes P, Rivera E, Rodríguez-Revuelto A, Flotats A, et al. Cardiac 123I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging 2008;35:1636-41.
7. Treglia G, Cason E, Giordano A. Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging 2010 [Epub ahead of print].
8. Verberne HJ, Habraken JB, van Eck-Smit BL, Agostini D, Jacobson AF. Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med Mol Imaging 2008;35:547-53. (Pubitemid 351661673)
9. Inoue Y, Suzuki A, Shirouzu I, Machida T, Yoshizawa Y, Akita F, et al. Effect of collimator choice on quantitative assessment of cardiac iodine 123 MIBG uptake. J Nucl Cardiol 2003;10:623-32. (Pubitemid 38035397)
10. Verberne HJ, Feenstra C, de Jong WM, Somsen GA, van Eck-Smit BL, Busemann Sokole E. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging 2005;32:1100-7. (Pubitemid 41339287)
11. Nakajima K, Matsubara K, Ishikawa T, Motomura N, Maeda R, Akhter N, et al. Correction of iodine-123-labeled metaiodobenzylguanidine uptake with multi-window methods for standardization of the heart-to-mediastinum ratio. J Nucl Cardiol 2007;14:843-51. (Pubitemid 350082578)
12. Flotats A, Carrio I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging2010;37:1802- 12.
13. Matsuo S, Nakajima K, Okuda K, Kawano M, Ishikawa T, Hosoya T, et al. Standardization of the heart-to-mediastinum ratio of 123I-labelled- metaiodobenzylguanidine uptake using the dual energy window method: feasibility of correction with different camera-collimator combinations. Eur J Nucl Med Mol Imaging 2009;36:560-6.
14. Okuda K, Nakajima K, Hosoya T, Ishikawa T, Konishi T, Matsubara K, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac iodine-123 MIBG imaging. J Nucl Cardiol 2011;18:82-9.
15. Matsuo S, Nakajima K, Yamashina S, Sakata K, Momose M, Hashimoto J, et al. Characterization of Japanese standards for myocardial sympathetic and metabolic imaging in comparison with perfusion imaging. Ann Nucl Med 2009;23:517-22.
16. Nakajima K. Normal values for nuclear cardiology: Japanese databases for myocardial perfusion, fatty acid and sympathetic imaging and left ventricular function. Ann Nucl Med 2010;24:125-35.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
18. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006;9:417-23. (Pubitemid 44253336)
19. Yamashina S, Yamazaki J. Role of MIBG myocardial scintigraphy in the assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol Imaging 2004;31:1353-5. (Pubitemid 39361929)
20. Merlet P, Hittinger L, Dubois-Randé JL, Castaigne A. Myocardial adrenergic dysinnervation in dilated cardiomyopathy: cornerstone or epiphenomenon? J Nucl Med 2002;43:536-9. (Pubitemid 34286351)
21. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.
22. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008;35:535-46.
23. Tamaki N. Guidelines for clinical use of cardiac nuclear medicine (Japanese Circulation Society 2005). Circ J 2005;69 Suppl IV 1125-202 (revision on the website 2010).
24. Sakata K, Shirotani M, Yoshida H, Kurata C. Physiological fluctuation of the human left ventricle sympathetic nervous system assessed by iodine-123-MIBG. J Nucl Med 1998;39:1667-71. (Pubitemid 28473509)
25. Chen J, Garcia EV, Galt JR, Folks RD, Carrio I. Optimized acquisition and processing protocols for I-123 cardiac SPECT imaging. J Nucl Cardiol 2006;13:251-60.